SCHEMBL5456326

SCHEMBL5456326

NC(=O)c1c(NC(=O)Nc2ccc(Br)cc2)sc2cc(O)ccc12

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
RAB9A P51151 1/20 0.43
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
CA12 O43570 2/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA9 Q16790 2/20 0.40
DYRK1A Q13627 3/20 0.39
DYRK1B Q9Y463 1/20 0.39
GRIK1 P39086 1/20 0.38
KCNH2 Q12809 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5447596 0.88 GAA (0.48) MEN1KMT2ANPC1ALDH1A1GAA
SCHEMBL5458283 0.88 MEN1 (0.43) MEN1KMT2ANPC1ALDH1A1GAA
SCHEMBL5451109 0.88 MEN1 (0.56) MEN1KMT2ANPC1ALDH1A1GAA
SCHEMBL5453616 0.87 TRPV1 (0.51) MEN1KMT2ANPC1ALDH1A1GAA
SCHEMBL5458832 0.87 MEN1 (0.47) MEN1KMT2ANPC1ALDH1A1GAA
SCHEMBL5459965 0.86 MDM2 (0.45) MEN1KMT2ANPC1ALDH1A1GAA
SCHEMBL5455862 0.85 BAZ1A (0.51) MEN1KMT2ANPC1ALDH1A1GAA
SCHEMBL5455604 0.85 MAPT (0.48) MEN1KMT2ANPC1ALDH1A1GAA
SCHEMBL17625474 0.85 CA12 (0.43) MEN1KMT2ANPC1ALDH1A1GAA
SCHEMBL5460392 0.85 RAB9A (0.49) MEN1KMT2ANPC1ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 MEN1 2891/4885KMT2A 4785/4885NPC1 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.